Loading...
XNASNVCT
Market cap112mUSD
Jan 10, Last price  
5.81USD
1D
-5.83%
1Q
-9.22%
IPO
-26.92%
Name

Nuvectis Pharma Inc

Chart & Performance

D1W1MN
XNAS:NVCT chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
-100.00%
00149,0000
Net income
-22m
L+18.49%
-10,000-12,886,000-18,787,000-22,260,000
CFO
-16m
L+17.66%
24,000-9,504,000-13,559,000-15,954,000

Profile

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
URL
https://nuvectis.com/
IPO date
Feb 04, 2022
Employees
11
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFY
2023‑122022‑122021‑122020‑12
Income
Revenues
149
 
Cost of revenue
45,794
38,468
Unusual Expense (Income)
NOPBT
(45,794)
(38,319)
NOPBT Margin
Operating Taxes
(298)
Tax Rate
NOPAT
(45,794)
(38,021)
Net income
(22,260)
18.49%
(18,787)
45.79%
Dividends
Dividend yield
Proceeds from repurchase of equity
5,289
31,879
BB yield
-4.08%
-33.58%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
(19,126)
(19,993)
Cash flow
Cash from operating activities
(15,954)
(13,559)
CAPEX
Cash from investing activities
Cash from financing activities
15,087
27,810
FCF
(45,794)
(38,021)
Balance
Cash
19,126
19,993
Long term investments
Excess cash
19,126
19,986
Stockholders' equity
(54,245)
(11,580)
Invested Capital
66,446
25,799
ROIC
ROCE
EV
Common stock shares outstanding
15,557
12,658
Price
8.34
11.20%
7.50
 
Market cap
129,743
36.67%
94,932
 
EV
110,617
95,344
EBITDA
(45,794)
(38,319)
EV/EBITDA
Interest
149
Interest/NOPBT